SCHEMBL20077367

SCHEMBL20077367

CS(=O)(=O)C[C@H](NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.68
GSTK1 Q9Y2Q3 1/20 0.68
GLO1 Q04760 2/20 0.63
NOD1 Q9Y239 8/20 0.45
FOLH1 Q04609 2/20 0.40
GRM8 O00222 1/20 0.39
GRM6 O15303 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GSR P00390 1/20 0.39
CYP1A2 P05177 1/20 0.39
GRIK1 P39086 1/20 0.39
GRM5 P41594 1/20 0.39
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA3 P42263 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
GRIA4 P48058 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22015916 0.89 PTGS1 (0.67) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL769485 0.88 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL13561368 0.88 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL10935016 0.88 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL1514772 0.88 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL22015845 0.88 PTGS1 (0.65) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL22015951 0.85 NOD1 (0.56) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL15473350 0.84 PTGS1 (0.75) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL14850413 0.84 PTGS1 (0.75) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL12181828 0.84 PTGS1 (0.75) PTGS1GSTK1GLO1NOD1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008287-B2 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine EPICENTRX, INC. (US) 2021-05-18 US disclosed
US-20200157047-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE EPICENTRX, INC. 2020-05-21 US disclosed
WO-2018071741-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE EPICENTRIX, INC. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008287-B2 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine AS3MT, SLC10A6, SLCO1B3 PTGS1 3711/4885GSTK1 737/4885GLO1 1067/4885
US-20200157047-A1 SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE AS3MT, SLC10A6, SLCO1B3 PTGS1 3711/4885GSTK1 737/4885GLO1 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.